The role of EGFR-targeting strategies in the treatment of head and neck cancer

With its targeted mechanism of action and synergistic activity with current treatment modalities, cetuximab is a potentially valuable treatment option for patients with recurrent and/or metastatic squamous cell cancer of the head and neck who have progressed on cisplatin-based chemotherapy. The use...

Full description

Saved in:
Bibliographic Details
Published in:OncoTargets and therapy 2012-01, Vol.5, p.127-131
Main Authors: Dequanter, Didier, Shahla, Mohammad, Paulus, Pascal, Lothaire, Philippe H
Format: Article
Language:English
Subjects:
Cancer
Cancer therapies
Care and treatment
cetuximab
Chemoradiotherapy
Chemotherapy
Head & neck cancer
Head and neck cancer
Health aspects
Immunotherapy
Monoclonal antibodies
Neck
Radiotherapy
Review
SCCHN
Targeted cancer therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:With its targeted mechanism of action and synergistic activity with current treatment modalities, cetuximab is a potentially valuable treatment option for patients with recurrent and/or metastatic squamous cell cancer of the head and neck who have progressed on cisplatin-based chemotherapy. The use of cetuximab in combination with radiotherapy as definitive treatment for locoregionally advanced squamous cell cancer of the head and neck is generally restricted to patients unfit to receive cisplatin-based chemoradiation, which is still considered the standard of care. The effect of this epidermal growth factor receptor antagonist occurs without any change in the pattern and the severity of toxicity usually associated with head and neck radiation.
ISSN:1178-6930
1178-6930
DOI:10.2147/OTT.S31863